CYTOMEDIX TO PRESENT AT RODMAN & RENSHAW
10TH ANNUAL HEALTHCARE
CONFERENCE ON WEDNESDAY, NOV. 12, 2008
Rockville, MD, Oct. 20, 2008 – Cytomedix, Inc. (AMEX:
GTF) today announced that Chief
Executive Officer Martin Rosendale will present an overview of the Company at the Rodman & Renshaw
10th Annual Healthcare Conference on Wednesday, November 12, 2008 at 2:25 p.m. Eastern time. The
conference will be held at the New York Palace Hotel in New York City.
In addition to the 20-minute presentation, Mr. Rosendale will be available for one-on-one meetings
throughout the day, before and after the 2:25 p.m. presentation. To register for the conference or to
request a one-on-one meeting with Cytomedix, please visit
http://www.rodmanandrenshaw.com/conferences?id=19. A web cast of the presentation will be available
live and for 90 days after the conference at
http://www.wsw.com/webcast/rrshq14/gtf or on the
Company’s website at www.cytomedix.com.ABOUT CYTOMEDIX
Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological
therapies, including the AutoloGel™ System, a device for the production of platelet rich plasma (“PRP”)
gel derived from the patient’s own blood. The AutoloGel™ System is cleared by the Food and Drug
Administration (“FDA”) for use on a variety of exuding wounds. The Company is currently pursuing a
multi-faceted strategy to penetrate the chronic wound market with its AutoloGel™ System. The Company
is also moving forward with the development of other product candidates in its pipeline. Most notably is
its CT-112 product, an anti-inflammatory peptide, that has shown promise in pre-clinical testing, and for
which the Company is currently preparing an Investigational New Drug (IND) application for the FDA.
Additional information regarding Cytomedix is available at: http://www.cytomedix.com
SAFE HARBOR STATEMENT
Statements contained in this press release not relating to historical facts are forward-looking statements
that are intended to fall within the safe harbor rule for such statements under the Private Securities
Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently
uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which
are beyond Cytomedix's ability to predict or control, including among others, the ability of the Company’s
management to achieve its strategic goals, the success of new sales initiatives, studies, or trials,
obtainment of broad reimbursement, development of CT-112, entrance into or results from any
collaborative agreements, ability to secure research grants, licensing activities, and development of other
technologies under the Company’s patents or products in its pipeline.
These forward-looking statements are subject to known and unknown risks and uncertainties that could
cause actual events to differ from the forward-looking statements. More information about some of these
risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission
by Cytomedix, Inc. Except as is expressly required by the federal securities laws, Cytomedix undertakes
no obligation to update or revise any forward-looking statements, whether as a result of new information,
changed circumstances or future events or for any other reason.
|
